SCYNEXIS
SCYXSCYNEXIS, Inc. is a biotechnology company focused on developing and commercializing a novel class of antifungal agents called fungerps (triterpenoids) to treat severe and drug-resistant fungal infections.
Earnings
Next report
Nov 4, 2026 (in 2 months)Competitors
By market cap
By revenue growth
Profile
SCYNEXIS, Inc. is a biotechnology company focused on developing and commercializing a novel class of antifungal agents called fungerps (triterpenoids) to treat severe and drug-resistant fungal infections. The company's lead platform addresses significant unmet medical needs in rare diseases and hospital-based infections, specifically targeting pathogens like Candida and Aspergillus. Its primary value proposition lies in providing oral and intravenous alternatives to existing antifungal classes that face increasing clinical resistance.
A pioneer in the triterpenoid antifungal class, holding a first-in-class FDA approval for vulvovaginal candidiasis while transitioning to a licensing-heavy model for its lead asset.
FAQ
- What is SCYNEXIS's market cap?
- SCYNEXIS (SCYX) has a market capitalization of $5.4M and trades on NASDAQ.
- Who are SCYNEXIS's competitors?
- SCYNEXIS's key competitors include Gilead Sciences, Merck, Pfizer, and others. These companies compete in similar markets and product categories.
- Who does SCYNEXIS partner with?
- SCYNEXIS's notable partners include GSK, Merck, Hansoh Pharmaceutical, and others.
- Where is SCYNEXIS headquartered?
- SCYNEXIS is headquartered in United States of America and employs approximately 29 people. It has been publicly traded since 2014.